Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog

Barinthus Biotherapeutics plc.

2025-Q3 EPS reported -$1.37

Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.
Cash and equivalents $75.7M as of Sept 30, down $12.1M from June 30; runway into 2027.
Announced all-stock merger with Clywedog; combined company renamed Clywedog Therapeutics Holdings, ticker CLYD, close expected H1 2026.
VTP-1000 celiac SAD data expected by end 2025; MAD data in H2 2026.
Impairment of $4.7M due to deal valuation; R&D expenses fell to $5.4M from $8.0M QoQ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.